大型製藥企業的藥物基因體學研究

本報告已在2011年12月21日停止出版。

簡介

目錄

Abstract

Introduction

Pharmacogenomics will revolutionize the drug industry by linking the right drug to the right patient. Several companies and regulatory agencies are leading the charge to implement this approach of developing targeted medicines. PGx's integration is inevitable; pharma companies must get on board now or risk being left behind.

Get the Answers You Need to Shape Your Strategy

Big pharma companies have become increasingly interested in PGx. These companies realize that PGx offers a way to develop better and safer drugs. Which companies are leading the charge to integrate PGx into drug discovery and development? Appropriate genetic markers and well-documented patient samples are critical to determining disease correlations. How are companies obtaining this information, and how are they using it to create personalized medicines? Although PGx is being integrated into many aspects of drug discovery and development, many regulatory and ethical challenges persist. What are the major issues remaining, and what are companies and regulatory agencies doing to overcome these challenges?

Table of Contents

• Contents
• Executive Summary
• Strategic Considerations
• Stakeholder Implications
• Pharmacogenomics in Practice
• Leaders in the Implementation of PGx
• Celera Genomics
• Illumina
• Perlegen Sciences
• Well-Documented Patient Data Are Paramount
• DeCode Genetics-Icelandic Population
• Spectrum Expert Commentary: Difficulties in Using Founder Populations
• The Mayo Clinic-Olmsted County Epidemiology Data
• Genizon-Quebec French Canadian Founder Population
• Industry's Current Use of Pharmacogenomics
• Preclinical Drug Development
• DeCode Genetics-Identifying New Drug Targets
• Improving Safety and Efficacy of New Drugs
• Patient Segmentation
• Genentech/Roche/Chugai's Trastuzumab (Herceptin)
• Clinical Data/Genaissance's Vilazodone
• Perlegen's MCC-555
• Encode's Information-Rich Clinical Trials
• Drug Dosing and Metabolism
• NeoPharm's LE-SN38
• Warfarin (Bristol-Myers Squibb's Coumadin)
• Azathioprine and Mercaptopurines
• Adverse Drug Reactions
• GlaxoSmithKline's Abacavir (Ziagen)
• Eli Lilly's Atomoxetine (Strattera)
• Post-Marketing Efficacy Issues
• Epidermal Growth Factor Receptor-Based Drugs
• Clinical Data and Genaissance's STRENGTH and CARING Studies
• Major Challenges
• Regulatory Issues
• Reimbursement, Ethical, and Legal Issues
• Spectrum Expert Commentary: FDA Establishes New Processes:
• Pharmacogenomic Data Submissions and a Drug-Test Codevelopment Pathway
• Outlook

Tables

• 1. Financial Position of Key PGx Leaders, FY05
• 2. Select Celera Collaborations
• 3. Disease Correlations Identified by Celera
• 4. Select Perlegen Collaborations
• 5. Populations for Disease Correlation and PGx Studies
• 6. Effect of Genotype on Drug-Drug Interactions
  • A. Examples of Different Categories of Biomarkers
• 7. Select PGx Diagnostics

Figures

• 1. Potential of PGx in Practice
• 2. Founder Populations
• 3. Genomewide Scans and SNP Mapping
• 4. Genome-Based Drug Doses for Antidepressants
• 5. UGT1A1 Genotype Testing Before Irinotecan Rx
  • A. Drug-Test Codevelopment Process

相關商品

製藥企業相關市場調查報告書

生物標記相關合作契約
Biomarker Partnering Terms and Agreements
價格 : US $ 2695
出版日期 : 2012年02月

最佳實務：轉譯研究-朝向產業轉換前進
Best Practices: Translational Research - Positive Steps on the Path to Industry Transformation
價格 : US $ 4500
出版日期 : 2011年12月

製藥產業的合作，授權，投資，收購與合併交易趨勢:2011年12月
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - December 2011
價格 : US $ 1000
出版日期 : 2011年12月

Decision Resources, Inc.發行的製藥相關市場調查報告書

傳染病疫苗開發平台:競爭檢討

Special Report: The Infectious Disease Vaccine Pipeline--A Competitive Review

價格 : US $ 9200

出版日期 : 2011年06月

感染疾病疫苗:未滿足需求和對醫藥品產業來說的機會

Special Report: Infectious Disease Vaccines--Unmet Needs and Opportunities for Pharma

價格 : US $ 9200

出版日期 : 2011年06月

自閉症譜系障礙:高未滿足需求創造出很大的市場機會

Special Report: Autism Spectrum Disorders--High Unmet Needs Create Significant Market Opportunities

價格 : US $ 9200

出版日期 : 2011年06月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!